Donanemab is a new drug that is considered to be the turning point for the treatment of Alzheimer's as the global trial has confirmed that it slows down the cognitive decline of patients. This is an antibody medicine which helps patients who are in the early stages of the disease as it clears the build-up of protein in the brain which occurs in cases of Alzheimer's.